Literature DB >> 7535779

Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells.

G Bellone1, M Geuna, A Carbone, S Silvestri, R Foa, G Emanuelli, L Matera.   

Abstract

The pituitary hormone prolactin (Prl) is known to act as a local regulator of immune cell function, and Prl-binding receptors (Prl-R) have been described to share distinctive features with the members of the newly described cytokine/hemopoietin receptor superfamily. Here we show that the hormone can functionally interact with lineage-specific hemopoietic factors. When highly purified progenitor cells (CD34+ve) were seeded in semisolid methylcellulose cultures in the presence of interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF), and erythropoietin (Epo), a selective enhancing effect of Prl on the formation of colony forming unit-granulocyte (CFU-G) and burst forming unit-erythroid (BFU-E) colonies was observed. The effect of the hormone was plotted as a bell shaped curve, with the optimal response at the supraphysiological concentration of 50 ng/ml. Limiting dilution analysis showed that Prl acted directly on hemopoietic progenitors. This was confirmed by the observation on the CD34+ve cells of Prl-binding sites reacting with the specific monoclonal antibodies (mAbs), U5 and PrR-7A. Immunoprecipitation of the metabolically labeled CD34+ve cells with the PrR-7A mAb revealed a structure of 43 kD under reducing conditions. Analysis of the early events associated with the Prl/Prl-R interaction showed an increased number of cells engaged in DNA and hemoglobin synthesis. Enhanced erythroid differentiation of CD34+ve cells in the presence of Prl was secondary to upmodulation of receptors for the lineage-specific factor Epo. Together these data demonstrate the existence of a functional interplay between Prl and hemopoietic factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535779     DOI: 10.1002/jcp.1041630202

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  Minireview: prolactin regulation of adult stem cells.

Authors:  Lucila Sackmann-Sala; Jacques-Emmanuel Guidotti; Vincent Goffin
Journal:  Mol Endocrinol       Date:  2015-03-20

2.  Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions.

Authors:  L Matera; A Galetto; M Geuna; K Vekemans; E Ricotti; M Contarini; F Moro; G Basso
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

3.  Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Lauro M Takeuchi; Konstantinos Hatzistergos; Henry Quevedo; Sarah M Selem; Adriana V Treuer; Courtney Premer; Wayne Balkan; Irene Margitich; Yun Song; Qinghua Hu; Joshua M Hare
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

4.  Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line.

Authors:  R Assandri; M Egger; M Gassmann; E Niggli; C Bauer; I Forster; A Gorlach
Journal:  J Physiol       Date:  1999-04-15       Impact factor: 5.182

5.  Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene.

Authors:  N D Horseman; W Zhao; E Montecino-Rodriguez; M Tanaka; K Nakashima; S J Engle; F Smith; E Markoff; K Dorshkind
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

6.  Human prolactin promotes human secondary immunoglobulin response in human/SCID mouse chimeras.

Authors:  Jian Zhang; Rui Sun; Zhigang Tian
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

7.  A novel potential role of pituitary gonadotropins in the pathogenesis of human colorectal cancer.

Authors:  Wojciech Marlicz; Agata Poniewierska-Baran; Sylwia Rzeszotek; Rafał Bartoszewski; Karolina Skonieczna-Żydecka; Teresa Starzyńska; Mariusz Z Ratajczak
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.